At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 37 enrolled
Drug / intervention
JTT-662 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single-blind, Randomized, Placebo-controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JTT-662 Administered for 28 Days in Subjects With Type 2 Diabetes Mellitus on Metformin Monotherapy
In Brief
A Phase 1 clinical trial evaluating JTT-662 and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 37 participants across 1 site.
Detailed Summary
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JTT-662 administered once daily for 28 days in subjects with Type 2 diabetes mellitus (T2DM) who are receiving metformin monotherapy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
Enrollment StartJun 2020
First PostedJul 2020
Primary CompletionFeb 2021
TodayJul 2026
First PostedJul 10, 2020
Enrollment StartJun 15, 2020
Primary CompletionFeb 17, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.0 years ago
Interventions
JTT-662drug
Active drug tablets containing JTT-662
Placebodrug
Placebo tablets matching in appearance to the active drug tablets